NCT07213674 2026-04-16
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3 Recruiting
Clinical Trials
217 trialsNCT03821792 2026-04-15
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06136650 2026-04-15
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT02123758 2026-04-13
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 1 Active not recruiting
NCT02257736 2026-04-13
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02960022 2026-04-13
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Inc
Phase 2 Recruiting
NCT03431350 2026-04-13
QUEST
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT03748641 2026-04-13
MAGNITUDE
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04497844 2026-04-13
AMPLITUDE
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04577833 2026-04-13
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04662580 2026-04-13
ARX517
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05818683 2026-04-13
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07406282 2026-04-09
Double-DARE
Bayer
Recruiting
NCT06136624 2026-04-08
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06392841 2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT06632977 2026-04-07
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT06785636 2026-04-07
P300
Pathos AI, Inc.
Phase 1/2 Recruiting
NCT06120491 2026-04-03
EvoPAR-PR01
AstraZeneca
Phase 3 Recruiting
NCT07005154 2026-04-02
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Astellas Pharma Inc
Phase 2 Recruiting
NCT03419234 2026-04-01
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04493853 2026-04-01
CAPItello-281
AstraZeneca
Phase 3 Active not recruiting
NCT03436654 2026-03-27
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05593497 2026-03-27
SNARE
VA Office of Research and Development
Phase 2 Recruiting
NCT06457919 2026-03-24
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT03360721 2026-03-16
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05171816 2026-03-11
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
AstraZeneca
Phase 3 Active not recruiting
NCT04179864 2026-03-10
CELLO-1
Ipsen
Phase 1/2 Terminated
NCT02703623 2026-03-06
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04748042 2026-03-06
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT05968599 2026-02-25
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Pfizer
Completed
NCT01314118 2026-02-24
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Janssen Biotech, Inc.
Phase 2 Completed
NCT03016741 2026-02-24
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Northwestern University
Phase 4 Active not recruiting
NCT06650579 2026-02-24
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University
Phase 3 Recruiting
NCT01786265 2026-02-20
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04947254 2026-02-19
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06616597 2026-02-19
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05137262 2026-02-18
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02861573 2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT03902951 2026-02-05
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03732820 2026-01-29
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT04734730 2026-01-28
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT03565835 2026-01-26
Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
Montefiore Medical Center
Phase 2 Completed
NCT04267887 2026-01-20
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT02125617 2026-01-14
uPARCRPC
Rigshospitalet, Denmark
Terminated
NCT01995058 2026-01-08
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Phase 2 Terminated
NCT02949284 2026-01-07
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
Rutgers, The State University of New Jersey
Phase 2 Active not recruiting
NCT05689021 2026-01-07
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Mayo Clinic
Phase 2 Active not recruiting
NCT06072196 2025-12-31
A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Pfizer
Completed
NCT06384222 2025-12-30
Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone
University of California, San Francisco
Phase 2 Recruiting
NCT06378866 2025-12-26
DIVINE
Mayo Clinic
Phase 2 Recruiting